{{Rsnum
|rsid=10435604
|Chromosome=8
|position=61240115
|Orientation=plus
|GMAF=0.2934
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 10.6 | 89.4
| HCB | 42.3 | 46.0 | 11.7
| JPT | 38.9 | 48.7 | 12.4
| YRI | 16.3 | 47.6 | 36.1
| ASW | 10.5 | 40.4 | 49.1
| CHB | 42.3 | 46.0 | 11.7
| CHD | 56.0 | 37.6 | 6.4
| GIH | 18.8 | 46.5 | 34.7
| LWK | 8.2 | 47.3 | 44.5
| MEX | 0.0 | 34.5 | 65.5
| MKK | 16.7 | 44.2 | 39.1
| TSI | 0.0 | 12.7 | 87.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10435604
|Name_s=
|Gene_s=CLVS1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.13, combined P value= 4.39E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470170
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10435604
|overall_frequency_n=38
|overall_frequency_d=128
|overall_frequency=0.296875
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}